Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31096050 | 1.00 | PDE4B (0.53) | PDE4BFPR2SLC6A4PDE4AHTR6 | |
| SCHEMBL31096321 | 0.91 | PDE4A (0.44) | PDE4BFPR2SLC6A4PDE4AHTR6 | |
| SCHEMBL21823754 | 0.91 | PDE4A (0.44) | PDE4BFPR2SLC6A4PDE4AHTR6 | |
| SCHEMBL31096114 | 0.82 | PDE4A (0.50) | PDE4BSLC6A4PDE4AHTR6 | |
| SCHEMBL133005 | 0.82 | PDE4A (0.50) | PDE4BSLC6A4PDE4AHTR6 | |
| SCHEMBL130569 | 0.80 | PDE4A (0.55) | PDE4BPDE4A | |
| SCHEMBL129356 | 0.80 | PDE4A (0.59) | PDE4BPDE4A | |
| SCHEMBL5704271 | 0.78 | PDE4A (0.57) | PDE4BPDE4A | |
| SCHEMBL7354727 | 0.78 | CA12 (0.56) | PDE4BPDE4A | |
| SCHEMBL7358705 | 0.77 | MAPT (0.52) | PDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | PDE4B 1/4885FPR2 4123/4885SLC6A4 940/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | PDE4B 1/4885FPR2 3899/4885SLC6A4 472/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | PDE4B 1/4885FPR2 3899/4885SLC6A4 472/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | PDE4B 1/4885FPR2 3899/4885SLC6A4 472/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | PDE4B 2/4885FPR2 4073/4885SLC6A4 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.